TokenPost topic
2 TokenPost stories are tagged Incyte. The newest appear first.
The study will combine petosemtamab and INCB161734 with chemotherapy as a potential first-line treatment.
Oct 25, 2026, 3:04 PM EDT · Business
Incyte announced Phase 3 results showing its tafasitamab plus lenalidomide regimen significantly improved progression-free survival in high-risk lymphoma patients.
Jun 14, 2026, 6:16 PM EDT · Business